Vivo Capital VIII, LLC
CIK 1618789 · last filed 2023-12-19
Vivo Capital VIII, LLC is a corporate insider who has filed 10 SEC Form 4 insider transactions across 6 companies since 2017. Across all open-market trades the lifetime net is −$20.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $47.3K across reported positions. The firm reports its address in Palo Alto, CA. 28 SEC filings were submitted jointly with Vivo Capital Fund VIII, L.P.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CRNX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
PALO ALTO, CA 94301
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BOLT | 10%+ Owner | 7,179 | $6.59 | $47.3K | -$559.5K | 1 | 2023-11-20 |
| Terns Pharmaceuticals, Inc. (TERN) Delisted | 10%+ Owner | 281,223 | $52.95 | $14.89M | $27.50M | 1 | 2022-12-23 |
| IPI Legacy Liquidation Co (IMPL) Delisted | 10%+ Owner | — | $0.24 | — | $0 | 1 | 2021-04-26 |
| Timber Pharmaceuticals, Inc. (BPMX) Delisted | 10%+ Owner | 26,439 | — | — | -$1.11M | 4 | 2019-06-27 |
| Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | 10%+ Owner | 210,373 | $84.95 | $17.87M | -$46.39M | 1 | 2019-03-25 |
| Nabriva Therapeutics plc (NBRV) Delisted | 10%+ Owner | 1,977 | $1.42 | $2.8K | $497.9K | 1 | 2017-09-18 |
Recent Filings
10 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-12-19 | — | Sell (S) | −1,725,000 | -$222.4K | |
| 2023-11-20 | BOLT | Sell (S) | −602,378 | -$559.5K | EDGAR |
| 2022-12-23 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Buy (P) | +3,793,100 | $27.50M | EDGAR |
| 2021-04-26 | IPI Legacy Liquidation Co (IMPL) Delisted | Other (J) | — | $0 | EDGAR |
| 2019-06-27 | Timber Pharmaceuticals, Inc. (BPMX) Delisted | Sell (S) | −327,870 | -$334.4K | EDGAR |
| 2019-03-25 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Sell (S) | −2,085,000 | -$46.39M | EDGAR |
| 2018-03-09 | Timber Pharmaceuticals, Inc. (BPMX) Delisted | Sell (S) | −2,000,000 | -$720.0K | EDGAR |
| 2018-01-31 | Timber Pharmaceuticals, Inc. (BPMX) Delisted | Conv (C) | +4,328,571 | $0 | EDGAR |
| 2017-11-13 | Timber Pharmaceuticals, Inc. (BPMX) Delisted | Sell (S) | −296,394 | -$59.3K | EDGAR |
| 2017-09-18 | Nabriva Therapeutics plc (NBRV) Delisted | Buy (P) | +52,631 | $497.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.